District of Columbia Clinical Trials Report — April 2026

For residents of the District of Columbia considering participation in clinical research, April 2026 brings important opportunities, particularly for those who wish to join studies before their enrollment windows close. A total of 54 clinical trials are slated to conclude recruitment within the next 90 days. Among these, 7 trials are actively seeking healthy volunteers, offering a chance to contribute to medical science without a specific health condition. Individuals interested in these time-sensitive opportunities should explore them promptly.

The trials nearing their close cover a range of health conditions, from chronic illnesses to specific cancer stages. Patients managing these conditions may find limited time to enroll in studies that could offer new treatment avenues. Conditions with trials closing soon include:

• Sickle cell disease
• Stage IV lung cancer AJCC V8
• Advanced lung non-small cell carcinoma
• Agoraphobia
• Alzheimer disease
• Anatomic Stage II breast cancer AJCC V8
• Anxiety disorders
• Anatomic Stage III breast cancer AJCC V8
• Argi deficiency
• Argininosuccinic aciduria

New Research Horizons: Pancreatic Cancer and HIV Prevention

This month, the District of Columbia welcomes 2 new clinical trials, matching the number of new studies that opened in March 2026. While the volume of new trials is modest, both studies address critical health challenges and are sponsored by notable organizations, offering residents access to cutting-edge research.

One significant new opportunity is a Phase 3 drug trial sponsored by Incyte Corporation:

• NCT07522073: "A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma." This pivotal study aims to enroll 588 participants globally to assess the effectiveness and safety of standard chemotherapy combined with or without INCB161734 for metastatic pancreatic ductal adenocarcinoma (PDAC). This research offers a crucial pathway for patients facing this aggressive cancer.

Another notable trial focuses on public health and prevention, sponsored by Westat:

• NCT07510048: "Combatting HIV Or Other STIs Early (CHOOSE) in an RCT of mHealth Tool Support." This Phase 2 study, designed for 200 participants, seeks to optimize and evaluate an integrated mHealth package called PrEP Choice. The goal is to improve HIV PrEP (pre-exposure prophylaxis) uptake and adherence among young people, as well as address other sexually transmitted infections. This trial represents an important step in leveraging technology for public health interventions.

The new trials this month are focused on several key areas:

• HIV
• HIV prevention
• Solid tumors
• STIs
• STIs prevention

Both new studies are located in Washington D.C., contributing to the city's robust research landscape. One of the new trials is a drug study, while the other falls under the 'OTHER' category, indicating a diverse approach to research methodologies.

Participation and Geographic Accessibility

The District of Columbia currently hosts a total of 826 clinical trials that are actively recruiting participants. These studies are distributed across 4 cities and conducted at 296 research sites, ensuring broad accessibility for residents. All 2 of the new trials this month are located within Washington D.C., reinforcing the city's role as a central hub for medical research in the region.

For those without specific health conditions, opportunities to contribute to medical research are available. One of the 2 new trials launched this month is accepting healthy volunteers. Statewide, a total of 94 clinical trials are currently recruiting healthy participants, providing numerous avenues for individuals to support scientific discovery.

Eligibility for new trials this month includes diverse demographics. One new study is open to children, and another is specifically designed for male participants. Additionally, one of the new trials includes older adults, ensuring that a wide age range can participate in advancing medical knowledge.

Looking ahead, the District of Columbia's clinical research community will continue to focus on these new and ongoing studies, particularly those addressing critical public health needs and advanced cancer treatments. The coming months are expected to bring further opportunities for residents to engage with innovative research initiatives.